Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with...

Full description

Bibliographic Details
Main Authors: Christos Sachpekidis, David B. Jackson, Theodoros G. Soldatos
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Pharmaceuticals
Subjects:
non-Hodgkin’s lymphoma
radioimmunotherapy
<sup>90</sup>Y-ibritumomab tiuxetan (Zevalin), <sup>131</sup>I-tositumomab (Bexxar), FDA’s Adverse Event Reporting System (FAERS), VigiBase
Online Access:https://www.mdpi.com/1424-8247/12/4/141

Internet

https://www.mdpi.com/1424-8247/12/4/141

Similar Items